Geothermal Developer Ignis H2 Energy Raises $12.5M in Series A First Close
19.2.2025 13:47:00 CET | Business Wire | Press release
Funds to Advance Exploration Projects in USA, Turkey, Indonesia & Italy
Ignis H2 Energy Inc. (“Ignis Energy”), a geothermal exploration and development startup, announced today the successful first closing of its Series A funding round, securing $12.5 million from a consortium of investors, including leading funds and private individuals. The funding round was led by alfa8 and includes a commitment from drilling contractor Nabors Industries, alongside investments from existing shareholders, private individuals, and family offices.
Advancing a Global, Risk-Balanced Geothermal Portfolio
Unlike other startups in the geothermal industry, Ignis Energy does not rely on a single technology or opportunity. Instead, it manages a risk-balanced portfolio of geothermal power-producing opportunities across high-enthalpy environments worldwide. By leveraging proven technologies and insights from a distinguished panel of geothermal experts, Ignis Energy diversifies risk while ensuring a steady pipeline of sustainable energy projects. The company has already secured promising geothermal opportunities in Turkey, Alaska, California, Nevada, and Italy.
Driven by a mission to provide affordable, reliable, and sustainable baseload geothermal energy, Ignis Energy integrates extensive expertise from the oil and gas sector into geothermal exploration and development. The company is pioneering the use of cutting-edge machine learning models to predict, locate, and explore geothermal resources more efficiently, leading to better drilling outcomes and lower project risk. With a portfolio spanning multiple geographies and geological formations, Ignis Energy is targeting the development of one gigawatt of documented producible geothermal reserves by 2030.
Strategic Investors Committed to Geothermal Innovation
Alfa8: Investing in a Sustainable Future -- alfa8 is committed to advancing technologies that accelerate the global shift toward sustainable energy solutions. With a strong focus on geothermal innovation and next-generation renewables, the firm backs forward-thinking pioneers redefining the energy landscape while ensuring environmental stewardship. Erin Glenn, COO of alfa8, emphasized the firm’s strategic approach: “As a patient capital investor, alfa8 is dedicated to funding transformative ventures that address the energy crisis, drive the adoption of geothermal energy, and push the frontiers of maritime decarbonization and critical sustainability initiatives.”
Nabors Industries: Driving the Future of Geothermal Exploration -- With a presence in over 20 countries, Nabors Industries is a leading provider of advanced technology for the energy industry. By leveraging its core competencies, particularly in drilling, engineering, automation, data science and manufacturing, Nabors aims to innovate the future of energy and enable the transition to a lower carbon world. Spearheading advancements in geothermal technologies and projects is a key focus of Nabors’ energy transition strategy.
Guillermo Sierra, VP, Strategic Initiatives at Nabors, asserted that “Ignis Energy will be a strong addition to our geothermal investment portfolio as we seek to catalyze breakthrough technologies and collaborate with experienced operators to deliver energy without compromise. We believe Ignis’ project portfolio and management team is best-in-class and we are pleased to collaborate with them on near-term projects and support their long-term growth, which we expect will include additional collaboration with Nabors’ other geothermal technology ventures.”
Richard Calleri, CEO of Ignis Energy stated “we are a geothermal exploration and development company focused on building a risk-balanced portfolio of geothermal power plants across key global markets. By combining proven technologies, expert knowledge, and advanced data analytics, Ignis Energy is unlocking the full potential of geothermal resources and accelerating the transition to a cleaner, more sustainable energy future.”
Marcus Oesterberg, COO of Ignis Energy added that “our approach is technology agnostic with a focus on high enthalpy and predominantly traditional geothermal resources that can be developed with today’s technology for power production.”
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219707620/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom